Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Drug Development Cooperation Yields Synthetic Route for Anti-Skin Cancer Compounds

By BiotechDaily International staff writers
Posted on 12 Aug 2013
Image: Investigators at The Scripps Research Institute have achieved the first efficient chemical synthesis of ingenol, a highly complex, anticancer substance found in the Euphorbia genus of plant, whose milky sap has long been used in traditional medicine (Photo courtesy of the Scripps Research Institute).
Image: Investigators at The Scripps Research Institute have achieved the first efficient chemical synthesis of ingenol, a highly complex, anticancer substance found in the Euphorbia genus of plant, whose milky sap has long been used in traditional medicine (Photo courtesy of the Scripps Research Institute).
Cooperation between a Danish pharmaceutical company and a renowned American research institute has resulted in development of a method for chemical synthesis of the anticancer drug ingenol, which up to now could only be inefficiently extracted from plant materials.

Ingenol is a diterpenoid with unique architecture and has derivatives possessing important anticancer activity, including the recently [US] Food and Drug Administration–approved Picato (ingenol mebutate), a first-in-class drug for the treatment of the precancerous skin condition actinic keratosis. Ingenol mebutate, which is applied topically, can destroy precancerous skin cells with unusual swiftness, while sparing healthy skin cells. The treatment has a direct cancer-cell-killing effect, and also induces an inflammatory reaction. Currently, the compound is extracted inefficiently from the plant Euphorbia peplus.

Investigators at the Danish pharmaceutical company LEO Pharma (Ballerup Denmark), the manufacturer of Picato, recently collaborated with colleagues at The Scripps Research Institute (La Jolla, CA, USA) in an attempt to arrive at method for chemical synthesis of the drug.

They reported in the August 1, 2013, online edition of the journal Science Express that they had succeeded in developing a 14-step synthetic method beginning with inexpensive (+)-3-carene and employing a two-phase design (syntheses of ingenol had been described in the past, but they all required more than 37 steps). This newly described synthesis allowed for the creation of fully synthetic analogs of bioactive ingenol derivatives and provided a strategic blueprint for chemical production.

These results validated the concept of two-phase terpene total synthesis as not only an academic curiosity, but also a viable alternative to isolation or bioengineering for the efficient preparation of polyoxygenated terpenoids at the limits of chemical complexity.

“I think that most organic chemists had considered ingenol beyond the reach of scalable chemical synthesis,” said senior author Dr. Phil S. Baran, professor of chemistry at The Scripps Research Institute. “With this study we rebut that argument conclusively, and there are many other complex natural compounds waiting to be synthesized using a strategy like ours—this is really just a glimpse of the future of chemical synthesis.”

“At the time, the only way to get the product was by a relatively lengthy extraction process from the E. peplus plant,” said Michael Sierra, director of external discovery at LEO Pharma. “We were hoping to get a more efficient synthetic route for production, as well as a method that would allow us to make new derivatives. It is a pretty amazing feat: the total synthesis of ingenol within a year and a half of starting our collaboration. It is great to work with a research group like this.”

Related Links:
Leo Pharma
The Scripps Research Institute



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.